Mobile health strategies: Should you build or partner for success?
With GlobalData figures showing the value of pharma’s 2023 digital therapeutics-related deals to have grown by 129% since 2018, and the year still not out, it is clear that projects such as companion apps are becoming an increasing priority for life science firms. Here, we debate the benefits of building versus partnering, and share some important considerations for a successful project.
With GlobalData figures showing the value of pharma’s 2023 digital therapeutics-related deals to have grown by 129% since 2018, and the year still not out, it is clear that projects such as companion apps are becoming an increasing priority for life science firms. Here, we debate the benefits of building versus partnering, and share some important considerations for a successful project.
What's Your Reaction?
